🧠 APOE4 Genotype Treatment Risk Stratification Simulator

APOE4 Allele Dose and Alzheimer's Disease Risk

APOE4 copy number shifts lifetime Alzheimer's risk and age of onset, placeholder sentence.

• Baseline: Non-carrier risk (Reference population risk level)
• ~3×: Heterozygous risk (Placeholder relative risk figure)
• ~8–12×: Homozygous risk (Placeholder relative risk figure)
• ~25%: Population ε4 frequency (Placeholder allele frequency)

Allele dose effect on amyloid pathology

Placeholder: dose-dependent effect of APOE4 on amyloid accumulation and onset age.

Genotype Testing Before Treatment Initiation

Pre-treatment APOE4 genotyping informs eligibility and counseling, placeholder sentence.

• PCR/genotyping: Testing method (Placeholder lab method note)
• ~1–2 weeks: Turnaround time (Placeholder turnaround estimate)
• Genetic counseling: Disclosure requirement (Placeholder policy note)
• Recommended: Guideline status (Placeholder guideline reference)

Testing workflow and result disclosure

Placeholder: genotyping workflow, informed consent, and result disclosure process.

ARIA Risk Correlation with APOE4 Genotype

ARIA-E and ARIA-H incidence rise sharply with ε4 allele count, placeholder sentence.

• ~5–9%: ARIA-E, non-carrier (Placeholder incidence figure)
• ~15–20%: ARIA-E, heterozygous (Placeholder incidence figure)
• ~30–35%: ARIA-E, homozygous (Placeholder incidence figure)
• Minority of cases: Symptomatic ARIA (Placeholder proportion note)

Mechanistic basis of genotype-linked ARIA risk

Placeholder: cerebral amyloid angiopathy burden links APOE4 dose to ARIA incidence.

Risk-Benefit Discussion Tailored by Genotype

Shared decision-making weighs efficacy against genotype-specific ARIA risk, placeholder.

• Individualized: Discussion focus (Placeholder counseling note)
• Encouraged: Family involvement (Placeholder guidance note)
• Reviewed: Alternative options (Placeholder note on alternatives)
• Formal consent: Documentation (Placeholder documentation note)

Structuring the shared decision conversation

Placeholder: structuring risk-benefit conversation by genotype and risk tolerance.

Genotype-Informed Monitoring Intensity

MRI monitoring frequency scales with genotype-based ARIA risk, placeholder sentence.

• Non-carrier: Standard schedule (Placeholder monitoring cadence)
• Heterozygous: Enhanced schedule (Placeholder monitoring cadence)
• Homozygous: Intensive schedule (Placeholder monitoring cadence)
• New ARIA signal: Escalation trigger (Placeholder escalation rule)

Scaling MRI surveillance to genotype risk

Placeholder: MRI surveillance intervals scaled by genotype-driven ARIA risk tier.

Placeholder key insight: genotype-tiered monitoring balances safety and access.